Shopping Cart
Remove All
Your shopping cart is currently empty
MK-6892 is a selective and full agonist for the high-affinity nicotinic acid receptor GPR109A (Ki: 4 nM; GTPγS EC50: 16 nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $88 | In Stock | In Stock | |
| 5 mg | $198 | In Stock | In Stock | |
| 10 mg | $297 | In Stock | In Stock | |
| 25 mg | $497 | In Stock | In Stock | |
| 50 mg | $689 | In Stock | In Stock | |
| 100 mg | $987 | - | In Stock | |
| 200 mg | $1,330 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $226 | In Stock | In Stock |
| Description | MK-6892 is a selective and full agonist for the high-affinity nicotinic acid receptor GPR109A (Ki: 4 nM; GTPγS EC50: 16 nM). |
| Targets&IC50 | GPR109A:4 nM (Ki), GPR109A:16 nM (EC50) |
| In vitro | MK-6892 effectively induces the internalization of GPR109A in U2OS β-arrestin2-RrGFP cells and demonstrates a potent EC50 of 74 nM in calcium mobilization assays [2]. |
| In vivo | MK-6892 is administered orally to WT and nicotinic acid (NA) receptor null mice on a C57Bl/6 genetic background. Following a 100 mg/kg dose, blood levels of MK-6892 reach 229 μM in WT mice and 148 μM in NA receptor null mice after 15 minutes, significantly exceeding the in vitro EC50 (240 nM). MK-6892 effectively suppresses plasma FFA in WT mice, but not in NA receptor null mice, indicating NA receptor-dependent FFA reduction [1]. |
| Molecular Weight | 386.4 |
| Formula | C19H22N4O5 |
| Cas No. | 917910-45-3 |
| Smiles | CC(C)(Cc1nc(no1)-c1ccc(O)cn1)C(=O)NC1=C(CCCC1)C(O)=O |
| Relative Density. | no data available |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (116.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.18 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.